top of page
Prof. Dr. Necdet Üskent, MD

Prof. Dr. Necdet Üskent, MD

Medical Oncology

Since 2005, he has been serving as a medical oncology and hematology specialist, as well as the coordinator of oncological sciences at Anadolu Medical Center.


EDUCATION


University

University of Ankara School of Medicine, 1971

 

Residency

GATA, Internal Medicine, 1975-1979


Fellowship

University of Texas, Hematology & Oncology, 1979-1982


Other

University of London Charing Cross Hospital-UK, Bone Marrow Transplantation, 1986 April-October (6 months)

University of Basel, Kantonsspital Basel-Switzerland, Loco-regional Chemotherapy, 1989 September-January (3 months)

University of London, Royal Free Hospital, Stem Cell Transplantation, 1998


BOARD CERTIFICATION 


Internal Medicine, 1979

Medical Oncology, 1983

Hematology, 1983


MEDICAL LICENSURE 


Texas license - licence number: G 1791

Georgia licence – licence number: 22971

ESMO Medical oncology certificate – certificate number: 258-495-1


PREVIOUS PROFESSIONAL POSITIONS


1982-1984 Assistant Professor of Internal Medicine, GATA Department of Internal Medicine

1984-1989 Associate Professor of Internal Medicine, GATA Department of Internal Medicine, Division of Medical Oncology

1989-2001 Professor of Internal Medicine, GATA Department of Internal Medicine-Director- Chief of Hematology &Oncology Department

2001-2006 2001-2006  Professor of Internal Medicine, Kadir Has University School of Medicine Chief of Internal Medicine Department


EDUCATION—TEACHING 


Medical School: GATA School of Medicine: Classes 3 , 4 and 6, 1984-2001

University of Marmara School of Medicine: Classes 3 and 4,1987-1990

Kadir Has University, School of Medicine: Classes 3 and 4, 2001-2006 Graduate School: Istanbul University Çapa Institute of Oncology, Courses for Doctorate Students, 1990-1992

Continuing Education: ESMO Courses in Antalya, Istanbul, and Ankara Medical Oncology Courses in National Cancer Congresses New Trends in Oncology-Istanbul, 2008 and 2009


EDUCATION—JOURNALS


Member of Editorial Board and Reviewer of

·       Journal of Hematology and Oncology (Turkey),

·       Cancer (Turkey),

·       Journal of Oncology (Turkey),

·       New Drugs (International)


MEMBERSHIPS


ASCO (American Society of Clinical Oncology)

ESMO (European Society of Medical Oncology)

National Society of Medical Oncology

Turkish Associaton of Hematology


INVITED VISITING PROFESSORSHIPS  


University of London, Charing Cross and Westminster Medical School,1986

University of London Royal Free Hospital, 1998


PRESENTATIONS AT NATIONAL MEETINGS 


More than 200 Oral Presentations in National Meetings*


PRESENTATIONS AT INTERNATIONAL MEETINGS

 

More than 100 abstracts and oral presentations in International Cogresses *

 

INTRAMURAL PRESENTATIONS 


Oncology Board, Grand Rounds and Journal Clubs weekly


CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS


Breast cancer, Lung cancer, Gastrointestinal Cancers,Lymphoma, Melanoma, Myeloma, Cancer Vaccines and Targeted therapies


RESEARCH INTERESTS


Cancer Vaccines and Gene Therapies

International Multi-National Multicentric and National Multicentric Phase 3 Studies:


  1. ISEL Study:  Gefitinib in Placebo randomised double blind phase III study in Previously Treated Resistent or Progressive    Non-Small Cell Lung Cancer, 2004


  2. Efficacy of Docataxel as a First Line Single Agent Compare to Docataxel+ Cisplatin in Stage III/IV Non-Small Cell Lung Cancer, Phase III, Randomised Study, 2000


  3. Florourasil+ Leucovorine vs Florourasil+  alpha Inteferon in metastatic Colorectal cancer, Phase III, Randomised Study, 1999


  4. Neoadjuvant FOLFIRI vs FOLFOX in the resectability of liver metastases in colo-rectal cancer,Randomized National Multicentric Study


  5. Anastrozol Farmacovijilans Study in Early Postmenapausal Breast Cancer Patients,in Turkey. Multicentric National Study (Coordinator), 2008


  6. Interferon Maintenance in Multiple Myeloma patients in plato phase, multinational, multicentric study, 1997


  7. A Phase III Clinical Trial to Evaluate the safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7. Compared to Dacarbazine(DTIC) or Temozolamide (TMZ) in Subjects with Recurren Metastatic Melanoma Randomized  2010


BIBLIOGRAPHY


More than 200 published articles in National and Internatinal Journals*

LookForMed Health Tourism 2024

bottom of page